

**PHENOTYPIC AND MOLECULAR
CHARACTERIZATION OF METHICILLIN-
RESISTANT
STAPHYLOCOCCUS AUREUS (MRSA) ISOLATES**



A THESIS SUBMITTED TO THE
CENTRAL DEPARTMENT OF MICROBIOLOGY
INSTITUTE OF SCIENCE AND TECHNOLOGY
TRIBHUVAN UNIVERSITY
NEPAL

FOR THE AWARD OF
DOCTOR OF PHILOSOPHY
IN MICROBIOLOGY

BY
DHARM RAJ BHATTA

May 2018

DECLARATION

Thesis entitled “**Phenotypic and molecular characterization of methicillin-resistant *Staphylococcus aureus* (MRSA) isolates**” which is being submitted to the Central Department of Microbiology, Institute of Science and Technology (IOST), Tribhuvan University, Nepal for the award of degree of Doctor of Philosophy (Ph D) is a research work carried out by me under direct supervision of Prof. Dr. Dwij Raj Bhatta, Central Department of Microbiology, Tribhuvan University and co supervised by Dr. Lina M Cavaco.

This research is original and has not been submitted earlier in part or full in this or any other form to any university or institute, here or elsewhere, for the award of any degree.

Dharm Raj Bhatta

May 2018

RECOMMENDATION

This is to recommend that **Mr. Dharm Raj Bhatta** has carried out research entitled “**Phenotypic and molecular characterization of methicillin-resistant *Staphylococcus aureus* (MRSA) isolates**” for the award of Doctor of Philosophy (Ph D) in **Microbiology** under our supervision. To our knowledge, this work has not been submitted for any other degree.

He has fulfilled all the requirements laid down by Institute of Science and Technology (IOST), Tribhuvan University, Kirtipur, for the submission of the thesis for the award of Ph D degree.

Dr. Dwij Raj Bhatta

Supervisor

Professor

Central Department of Microbiology,

Tribhuvan University, Kirtipur, Kathmandu, Nepal.



Dr. Lina M. Cavaco

Co-Supervisor

Research group for Genomic epidemiology,

National Food Institute,

Technical University of Denmark,

Denmark.

May 2018

LETTER OF APPROVAL

On the recommendation of Prof. Dr. **Dwij Raj Bhatta**, this Ph D thesis submitted by **Dharm Raj Bhatta**, entitled “**Phenotypic and molecular characterization of methicillin resistant *Staphylococcus aureus* (MRSA) isolates**” is forwarded by Central Department Research Committee (CDRC) to the Dean, IOST, Tribhuvan University.

Dr. Megha Raj Banjara, Ph D

Head

Central Department of Microbiology,

Tribhuvan University

Kirtipur, Kathmandu, Nepal.

ACKNOWLEDGEMENTS

I would like to express my gratitude to respected supervisors Professor **Dr. Dwij Raj Bhatta**, Central Department of Microbiology, Tribhuvan University, Kirtipur, Kathmandu, Nepal and **Dr. Lina M. Cavaco**, Research group for Genomic epidemiology, National Food Institute, Technical University of Denmark, for their regular support, advice and guidance to complete the research work.

I am thankful to **Dr. Shishir Gokhale**, Professor and Head, Department of Microbiology, Manipal College of Medical Sciences (MCOMS), Pokhara, Nepal for his invaluable inspiration, encouragement and support. I am grateful to **Dr. Niranjan Nayak**, Professor, Department of Microbiology, Manipal College of Medical Sciences (MCOMS), Pokhara, Nepal for his expert advice and technical support. I would like to acknowledge all the faculty members, staff and Post graduate students of Microbiology department, Manipal Teaching Hospital, Pokhara for their help and support.

It is my pleasure to extend deep gratitude to **Dr. Gopal Nath**, Professor and Head, Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University (BHU), Varanasi, India for his guidance in molecular work. I am thankful to Mr. Kush Kumar, for his help in molecular work.

I express my deep gratitude to my family members for continuous inspiration and support. I am also thankful to **Dr. Anjana Singh, Dr. Megha Raj Banjara** and **Mr. Binod Lekhak**, Central Department of Microbiology, Tribhuvan University, Kirtipur, Kathmandu, Nepal, for their help and support. I would like to thank all my friends and colleagues for their direct and indirect help. I am grateful to **University Grant Commission (UGC)**, Nepal for financial support. Last but not the least; I would like to thank all the patients of Manipal Teaching Hospital for their participation.

Dharm Raj Bhatta

May 2018

ABSTRACT

Methicillin-resistant *Staphylococcus aureus* (MRSA) is one of the major causes of hospital and community acquired infections. Drug resistance among Staphylococci is global burden which is associated with significant morbidity and mortality around the world. This study was conducted to determine the prevalence of MRSA, antibiotic resistance pattern of the isolates and prevalence of Panton Valentine leukocidin (*PVL*) genes among MRSA isolates. This study was conducted for a period of three years (2012-2015) at the Manipal Teaching Hospital, Pokhara, Nepal.

A total of 400 isolates were collected from various clinical specimens including hospital units (Operation theaters and Intensive Care Units). Antibiotic susceptibility testing was performed by Kirby-Bauer disc diffusion method. Primary screening for MRSA was performed by disc diffusion test with cefoxitin (30 µg) and oxacillin (1 µg) discs, further confirmed by cefoxitin MIC test and detection of *mecA* gene by Polymerase Chain Reaction (PCR). Inducible clindamycin resistance was detected by D test. Multiplex PCR was used for the detection of *PVL* genes. Biofilm was detected by microtitre plate method.

Out of 400 *S. aureus* isolates, 139 (34.7%) were MRSA. Among the MRSA isolates, 74 (53.2%) were from inpatients, 58 (41.7%) isolates were from outpatients and 7 (5%) isolates were from hospital units (OT and ICUs). More than 65% of the MRSA isolates were resistant to ciprofloxacin, erythromycin and cotrimoxazole while less than 15% were resistant to amikacin, clindamycin and tetracycline. None of the isolate was resistant to vancomycin. Inducible clindamycin resistance was found in 54 (25.4%) isolates. A total of 148 isolates of *S. aureus* were tested for biofilm assay, 94 (63.5%) were MRSA and 54 (36.5%) were MSSA. Biofilm was detected in 32.4% (48/148) of the isolates. Out of the total of 94 MRSA isolates tested, 39 (41.5%) were biofilm producers. Panton Valentine leukocidin (*PVL*) genes were detected in 79 (56.8 %) of the 139 MRSA isolates. Majority (75.5%) of *PVL* positive strains were isolated from pus samples. High prevalence (90.4%) of *PVL* among community acquired MRSA was found and only 7.1% hospital acquired MRSA were positive for *PVL* genes. No *PVL* genes were detected

among the hospital environmental isolates. Thus, *PVL* can be used as marker for community acquired MRSA. Antibiotic resistance in *PVL* negative MRSA isolates was higher as compared to *PVL* positive MRSA. Out of 112 hospital staff tested, only 8 (7.1%) were found positive for MRSA nasal carrier.

This study showed a high prevalence of MRSA in our hospital. There is need for regular surveillance of antibiotic resistance, standardization of laboratory methods for detecting methicillin resistance and performing antibiotic susceptibility testing in developing countries like Nepal. Screening of erythromycin resistant isolates would minimize clinical failures associated with clindamycin therapy. Association of *PVL* genes among community acquired MRSA may increase their virulence and is a matter of concern. Biofilm formation by MRSA isolates is challenging for clinicians as majority of biofilm producing MRSA isolates were found multidrug resistant.

Key words: Antibiotic resistance, Methicillin-resistant *Staphylococcus aureus* (MRSA), *mecA*, *PVL*, Biofilm, Clinical specimens.

LIST OF ACRONYMS AND ABBREVIATIONS

| | |
|---------|---|
| AIDS | Acquired immunodeficiency syndrome |
| AST | Antibiotic susceptibility testing |
| ATCC | American type culture collection |
| CDC | Centers for disease control and prevention |
| CA-MRSA | Community acquired methicillin resistant <i>Staphylococcus aureus</i> |
| CLSI | Clinical and laboratory standards institute |
| CNS | Coagulase negative Staphylococci |
| HA-MRSA | Hospital acquired methicillin resistant <i>Staphylococcus aureus</i> |
| HCW | Health care worker |
| ICU | Intensive care unit |
| MDR | Multidrug resistant |
| MIC | Minimal inhibitory concentration |
| MRSA | Methicillin resistant <i>Staphylococcus aureus</i> |
| MSSA | Methicillin sensitive <i>Staphylococcus aureus</i> |
| NCCLS | National committee for clinical laboratory standards |
| NNIS | National nosocomial infections surveillance |
| OPD | Outpatient department |
| OT | Operation theater |
| PBP | Penicillin binding protein |

| | |
|------------|--|
| PCR | Polymerase Chain Reaction |
| <i>PVL</i> | Panton Valentine leukocidin |
| RRS | Regional resistance surveillance |
| SCC | Staphylococcal cassette chromosome |
| SSSS | Staphylococcal scalded skin syndrome |
| SSTI | Skin and soft tissue infections |
| TSS | Toxic shock syndrome |
| UTI | Urinary tract infection |
| VAP | Ventilator associated pneumonia |
| VISA | Vancomycin intermediate <i>Staphylococcus aureus</i> |
| VRSA | Vancomycin resistant <i>Staphylococcus aureus</i> |

LIST OF TABLES

| | Page No. |
|---|----------|
| Table 1: Frequency of <i>S. aureus</i> and MRSA in various specimens----- | 57 |
| Table 2: Clinical conditions associated with MRSA infections----- | 58 |
| Table 3: Department/unit wise distribution of MRSA isolates----- | 59 |
| Table 4: Distribution of <i>S. aureus</i> and MRSA among hospital staff----- | 60 |
| Table 5: Antibiotic resistance pattern of MSSA and MRSA isolates----- | 61 |
| Table 6: Antibiotic resistance pattern of MRSA and its distribution in OPD & ward----- | 62 |
| Table 7: Cefoxitin MIC values and <i>mecA</i> positivity among MRSA isolates---- | 62 |
| Table 8: Distribution of <i>PVL</i> genes among MRSA isolates from different specimen----- | 65 |
| Table 9: Antibiotic resistance pattern of <i>PVL</i> positive and <i>PVL</i> negative MRSA isolates----- | 66 |
| Table 10: Biofilm production among MRSA and MSSA isolates----- | 69 |
| Table 11: Multidrug resistance amongst biofilm producing & non biofilm producing <i>S. aureus</i> ----- | 69 |
| Table 12: Biofilm producers and biofilm non producers <i>S. aureus</i> from various clinical specimens----- | 69 |

LIST OF FIGURES

| | Page No. |
|---|-----------------|
| Figure 1: Distribution of sources of MRSA isolates----- | 59 |
| Figure 2: Antibiotic resistance pattern of <i>S. aureus</i> ----- | 61 |
| Figure 3: Distribution of MDR MRSA and Non MDR MRSA----- | 63 |
| Figure 4: Distribution of hospital and community acquired MRSA----- | 63 |
| Figure 5: MRSA distribution: male, female & hospital environmental isolates---- | 64 |
| Figure 6: D-test positive MRSA and MSSA isolates----- | 64 |
| Figure 7: Distribution of <i>PVL</i> positive MRSA isolates among male patients, female patients & hospital environmental isolates----- | 66 |
| Figure 8: Distribution of <i>PVL</i> genes among CA-MRSA & HA-MRSA----- | 67 |
| Figure 9: Comparison of <i>PVL</i> positive MDR MRSA & <i>PVL</i> negative MDR MRSA----- | 67 |

TABLE OF CONTENTS

| | Page No. |
|--|-----------------|
| Declaration | i |
| Recommendation | ii |
| Letter of Approval | iii |
| Acknowledgements | iv |
| Abstract | v |
| List of Acronyms and Abbreviations | vii |
| List of Tables | ix |
| List of Figures | x |
| | |
| CHAPTER 1..... | 1-8 |
| | |
| 1. INTRODUCTION | |
| 1.1 <i>Staphylococcus aureus</i> | 1 |
| 1.1.1 Panton Valentine leukocidin..... | 4 |
| 1.1.2 Biofilm..... | 5 |
| 1.2 Rationale..... | 7 |
| 1.3 Objectives..... | 8 |
| | |
| CHAPTER 2..... | 9-43 |

2. LITERATURE REVIEW

| | |
|---|----|
| 2.1 Staphylococci..... | 9 |
| 2.1.1 Taxonomy..... | 9 |
| 2.1.2 Historical review of Staphylococci..... | 10 |
| 2.2 <i>Staphylococcus aureus</i> | 10 |
| 2.3 Biochemical characteristics..... | 11 |
| 2.4 Resistance to physical & chemical agents..... | 11 |
| 2.5 Extracellular products..... | 11 |
| 2.5.1 Capsular polysaccharide..... | 12 |
| 2.5.2 Protein A..... | 12 |
| 2.5.3 Toxins and enzymes..... | 12 |
| 2.5.4 Exotoxins..... | 13 |
| 2.5.4.1 Alpha hemolysin..... | 13 |
| 2.5.4.2 Beta toxin..... | 13 |
| 2.5.4.3 Delta toxin..... | 13 |
| 2.5.4.4 Gamma toxin..... | 14 |
| 2.5.5 Leukocidin..... | 14 |
| 2.5.6 Exofoliate toxins..... | 15 |
| 2.5.7 Superantigens..... | 15 |
| 2.5.7.1 Enterotoxin..... | 15 |
| 2.5.7.2 Toxic Shock Syndrome Toxin..... | 16 |
| 2.5.8 Other extracellular proteins..... | 16 |
| 2.5.8.1 Coagulase..... | 16 |
| 2.5.8.2 Staphylokinase..... | 17 |
| 2.5.8.3 Other enzymes..... | 17 |
| 2.5.9 Biofilm..... | 17 |
| 2.6 Epidemiology..... | 20 |
| 2.7 Coagulase negative Staphylococci..... | 27 |
| 2.8 MRSA colonization among health care workers | 28 |
| 2.9 Staphylococcal diseases..... | 30 |
| 2.9.1 Skin and soft tissue infections..... | 30 |

| | |
|---|----|
| 2.9.1.1 Cellulitis..... | 31 |
| 2.9.1.2 Impetigo..... | 31 |
| 2.9.1.3 Folliculitis..... | 31 |
| 2.9.1.4 Furuncle..... | 32 |
| 2.9.1.5 Wound infections..... | 32 |
| 2.9.1.6 Decubitus ulcers..... | 32 |
| 2.9.2 Respiratory infections..... | 32 |
| 2.9.3 Urinary tract infections..... | 33 |
| 2.9.4 Systemic infections..... | 34 |
| 2.9.5 Bone and joint infections..... | 35 |
| 2.10 Antibiotic resistance..... | 36 |
| 2.11 MRSA testing methods..... | 38 |
| 2.11.1 Disc diffusion methods..... | 38 |
| 2.11.2 Epsilometer test..... | 39 |
| 2.11.3 Agar screening method..... | 39 |
| 2.11.4 Chromogenic agar..... | 39 |
| 2.11.5 Latex agglutination..... | 39 |
| 2.11.6 Automated methods..... | 40 |
| 2.11.7 Quenching fluorescence method..... | 40 |
| 2.11.8 Molecular methods..... | 40 |
| 2.12 Classification of MRSA..... | 41 |
| 2.12.1 Hospital acquired MRSA..... | 41 |
| 2.12.2 Community acquired MRSA..... | 42 |

CHAPTER 3.....44-56

3. MATERIALS AND METHODS

| | |
|-----------------------------|----|
| 3.1 Study site..... | 44 |
| 3.2 Duration of study..... | 44 |
| 3.3 Sample size..... | 44 |
| 3.4 Inclusion criteria..... | 44 |
| 3.5 Exclusion criteria..... | 44 |

| | |
|--|----|
| 3.6 Sample collection, processing & identification of <i>S. aureus</i> | 44 |
| 3.6.1 Specimen collection..... | 44 |
| 3.6.1.1 Collection of nasal swab from hospital staff..... | 45 |
| 3.6.1.2 Sampling from hospital environment..... | 45 |
| 3.6.2 Processing of specimen..... | 45 |
| 3.6.3 Identification of <i>S. aureus</i> | 46 |
| 3.6.3.1 Colony morphology..... | 46 |
| 3.6.3.2 Gram's stain..... | 46 |
| 3.6.3.3 Catalase test..... | 47 |
| 3.6.3.4 Coagulase test..... | 47 |
| 3.6.3.4.1 Slide coagulase test..... | 47 |
| 3.6.3.4.2 Tube coagulase test..... | 48 |
| 3.6.3.5 DNase test..... | 49 |
| 3.6.3.6 Mannitol fermentation test..... | 49 |
| 3.7 Phenotypic characterization of <i>S. aureus</i> | 50 |
| 3.7.1 Antibiotic susceptibility testing..... | 50 |
| 3.7.2 Screening tests for MRSA..... | 51 |
| 3.7.3 Detection of MIC..... | 52 |
| 3.7.4 Detection of inducible clindamycin resistance..... | 52 |
| 3.8 Genotypic characterization of MRSA isolates..... | 53 |
| 3.8.1 DNA extraction..... | 53 |
| 3.8.2 Detection of <i>mecA</i> gene..... | 54 |
| 3.8.3 Detection of <i>mecA</i> and <i>PVL</i> genes by PCR..... | 54 |
| 3.9 Detection of biofilm..... | 55 |
| 3.10 Data analysis..... | 56 |
| 3.11 Ethical clearance..... | 56 |

CHAPTER 4.....57-80

4. RESULTS AND DISCUSSION

| | |
|--|----|
| 4.1 Clinical and microbiological profile of <i>Staphylococcus aureus</i> (MRSA & MSSA)..... | 57 |
|--|----|

| | |
|--|---------------|
| 4.2 Distribution of Panton Valentine leukocidin (<i>PVL</i>) genes among MRSA..... | 65 |
| 4.3 Biofilm assay among MRSA and MSSA..... | 68 |
| 4.4 Discussion..... | 70 |
| 4.4.1 Drug resistance among <i>S. aureus</i> and MRSA..... | 70 |
| 4.4.2 MRSA and <i>PVL</i> genes..... | 75 |
| 4.4.3 MRSA and Biofilm..... | 78 |
| | |
| CHAPTER 5..... | 81-82 |
| 5. CONCLUSIONS AND RECOMMENDATIONS | |
| 5.1 Conclusions..... | 81 |
| 5.2 Recommendations..... | 82 |
| | |
| CHAPTER 6..... | 83-85 |
| 6. SUMMARY | |
| | |
| REFERENCES..... | 86-115 |
| | |
| APPENDIX | |